AGIC Capital, a growth-oriented private equity firm with $2.2 billion of assets under management, has acquired a majority stake in ATEC Pharmatechnik (ATEC). The sellers, ATEC’s founder & CEO, Hans-Werner Mumm, and family-backed Mittelstand investor HANNOVER Finanz Group, will remain invested in the company, and Hans-Werner Mumm will continue to act as its CEO.
AGIC Capital (AGIC), a growth-oriented private equity firm with $2.2 billion of assets under management, has acquired a majority stake in ATEC Pharmatechnik (ATEC). The sellers, ATEC’s founder & CEO, Hans-Werner Mumm, and family-backed Mittelstand investor HANNOVER Finanz Group, will remain invested in the company, and Hans-Werner Mumm will continue to act as its CEO.
ATEC is a manufacturer of aseptic processing solutions, primarily used in pharmaceutical manufacturing and bioprocessing applications, with a customer base that includes the top 10 global pharmaceutical companies. ATEC’s products include stopper and cap processing systems used for aseptic filling, RTP transfer ports and ancillary single-use transfer bag solutions. These mission-critical technologies enable ATEC’s customers to establish safe and reliable manufacturing process environments.
This is anticipated to be the first of several acquisitions as AGIC builds a specialty process technologies platform focused on pharmaceutical and biopharmaceutical end markets.
ATEC and HANNOVER Finanz were advised by Macquarie Capital with Latham & Watkins LLP advising the sellers, while AGIC was supported by White & Case LLP in connection with the acquisition.
